Aphria, Aurora Among Top Performers As Canadian Cannabis Sales Spike
Canada’s recreation cannabis sales grew by 19% in March to reach CA$181.1 million ($131.5 million), ahead of most U.S. states, according to Cantor Fitzgerald.
Analyst Pablo Zuanic said that Canada’s March sales data was significantly ahead of Cantor’s mid-single digit estimate, partly due to pantry loading, but also on account of continued Cannabis 2.0 rollouts.
Ratings And Price Targets
Cantor analyst Pablo Zuanic maintained the following ratings and price targets on cannabis stocks:
Overweight
Aurora Cannabis Inc. (NYSE: ACB) with a CA$27 price target.
Aphria Inc. (NYSE: APHA) with a CA$9.55 price target.
OrganiGram Holdings Inc (NASDAQ: OGI) with a price target of CA$5.60.
Neutral
Canopy Growth Corp (NYSE: CGC) with a price target of CA$25.
Tilray Inc (NASDAQ: TLRY) with a price target of $8.
Underweight
Hexo Corp (NYSE: HEXO) with a price target of CA$0.72.
Cantor's Cannabis Takeaways
Comparing Canada’s 17th month of recreational cannabis sales with Colorado's figures indicates that the country’s market may grow to CA$14 billion by the end of 2024, Zuanic said in the industry note.
So far, the best performers in the first quarter are Aphria, with 53% sales growth, and Aurora Cannabis and Tilray, with sales growth in the mid-20% range, the analyst said.
Canopy Growth is scheduled to report its March quarter results Friday.
Zuanic named Aphria and Aurora Cannabis as top picks.
Related Links:
Canopy Growth Set To Become Cannabis Sector Leader, Says BofA
The Week In Cannabis: A Great Week For Stocks Driven By Confusion, Aurora's Rally, New Advisors To Benzinga
Courtesy photo
Analista: Aphria y Aurora Cannabis Posicionados para Liderar Ventas en Canadá
Latest Ratings for APHA
May 2020 | Cantor Fitzgerald | Maintains | Overweight | |
May 2020 | Cantor Fitzgerald | Maintains | Overweight | |
Apr 2020 | CIBC | Maintains | Neutral |
View More Analyst Ratings for APHA
View the Latest Analyst Ratings
See more from Benzinga
Cantor Fitzgerald Says Aurora Cannabis Sell-Off Creates Entry Point
Monthly Canadian Cannabis Sales Increased Ahead Of Coronavirus Pandemic
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.